Professional
Formal
IVT
tumor-agnostic therapy
Treatment approach based on specific biomarkers regardless of the cancer's primary anatomical site.
Full Definition
Tumor-agnostic therapy represents a paradigm shift in cancer treatment where therapeutic decisions are based on specific molecular characteristics rather than the anatomical location where the cancer originated. This approach recognizes that cancers with shared molecular drivers may respond similarly to targeted treatments regardless of their tissue of origin. Regulatory approvals for tumor-agnostic indications reflect the growing importance of precision medicine and biomarker-driven treatment selection.
Usage
Usage note: Hyphenate when used as compound modifier. Emphasize biomarker dependence.
In Context
- "The FDA granted tumor-agnostic approval for the NTRK inhibitor across multiple cancer types." — Regulatory update
- "Tumor-agnostic therapy selection required comprehensive genomic profiling regardless of primary site." — Treatment protocol
Also known as
site-agnostic therapy
histology-independent treatment
Contrasted with
site-specific therapy
organ-based treatment
Don't confuse with
broad-spectrum therapy
pan-cancer treatment